RHOBTB2 (Rho-related BTB domain containing 2) by Schenkova, Kristina et al.
Gene Section 
Review 
Atlas Genet Cytogenet Oncol Haematol. 2016; 20(10) 516 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology 
INIST-CNRS OPEN ACCESS JOURNAL 
RHOBTB2 (Rho-related BTB domain containing 
2) 
Kristina Schenková, Shuo Cai, Francisco Rivero 
Centre for Cardiovascular and Metabolic Research, The Hull York Medical School, University of 
Hull, Cottingham Road, Hull HU6 7RX, UK; kristina.schenkova@hyms.ac.uk, CaiS@cardiff.ac.uk, 
francisco.rivero@hyms.ac.uk 
Published in Atlas Database: February 2016 
Online updated version : http://AtlasGeneticsOncology.org/Genes/RHOBTB2ID42109ch8p21.html 
Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/66085/02-2016-RHOBTB2ID42109ch8p21.pdf 
DOI: 10.4267/2042/66085
This article is an update of : 
Schenková K, Rivero F. RHOBTB2 (Rho-related BTB domain containing 2). Atlas Genet Cytogenet Oncol Haematol 2009;13(11) 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. 
© 2016 Atlas of Genetics and Cytogenetics in Oncology and Haematology 
Abstract 
RhoBTB2 is one of the three members of the 
RhoBTB family. All RhoBTB proteins are 
characterized by a GTPase domain followed by a 
proline-rich region, a tandem of two BTB domains 
and a C-terminal putative RING finger domain. 
RHOBTB2 is a putative tumour suppressor gene. 
Expression of RHOBTB2 has been found decreased 
in breast, lung and bladder tumors, head and neck 
squamous cell carcinoma and osteosarcoma. 
Decreased expression is often the result of promoter 
methylation. Mutations are uncommon. The role of 
RhoBTB2 in tumorigenesis is unknown but may be 
related to its function as a component of Cullin 3-
dependent ubiquitin ligase complexes regulating the 
cell cycle and apoptosis. 
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Identity 
HGNC (Hugo): RHOBTB2 
Location: 8p21.3 
Other names: DBC2, KIAA0717 
Local order: The RHOBTB2 locus is placed in a 
region of chromosome 8 (8p22-8p21.3) that exhibits 
frequent allelic imbalance and contains several 
tumor related genes. 
DNA/RNA 
Description 
The RHOBTB2 gene spans over 20 Kbp genomic 
DNA and consists of 10 exons, 9 coding exons and 
one exon in the 5'UTR (Figure 1). The coding 
sequence of RHOBTB2 is 2184 nucleotides long. 
The promoter region of RHOBTB2 has CpG islands. 
Gene structure of RHOBTB2. Boxes represent exons. The coding region is represented in blue. 
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Architecture of RhoBTB proteins. The figure shows the three human (Hs) RhoBTB subfamily members as well as the Drosophila 
(Dm) and Dictyostelium (Dd) orthologues. The simplified phylogenetic tree on the left illustrates the relationship among the 
proteins (overall percentage similarity between branches). The different domains are indicated with colours. 
 
 
Transcription 
There is no evidence of alternatively spliced 
transcripts. 
Protein 
Note 
RhoBTB2 is one of the three members of the 
RhoBTB family in vertebrates. The RhoBTB family 
was identified during the study of the genes encoding 
Rho-related proteins in the lower eukaryote 
Dictyostelium discoideum (Rivero et al., 2002). All 
three RhoBTB proteins may be implicated in 
tumorigenesis. 
Description 
RhoBTB2 is 727 amino acids long. All RhoBTB 
proteins share the same domain architecture: a 
GTPase domain is followed by a proline-rich region, 
a tandem of two BTB domains and a C-terminal 
region (Figure 2) 
The GTPase domain is Rho-related and contains a 
Rho insert that is longer than usual, two insertions 
and one deletion, as well as a few deviations from 
the GTPase consensus of most Rho GTPases. Chang 
et al. (2006) reported the inability of this domain to 
bind GTP. However the construct used in that study 
lacked one of the GTPase motifs, G5. Subsequent 
work with the full-length protein and a more 
complete GTPase domain showed that this domain is 
actually able to bind GTP (Manjarrez et al., 2014). 
The proline-rich region links the GTPase to the first 
BTB domain. This region could act as a SH3 
domain-binding site. 
The BTB domain (broad complex, tramtract and 
bric-a-brac) is an evolutionary conserved protein-
protein interaction domain that participates in 
homomeric and heteromeric associations with other 
BTB domains. The BTB domain was also identified 
as a component of multimeric cullin3-dependent 
ubiquitin ligase complexes. The first BTB domain is 
bipartite, being interrupted by an insertion of 
unknown function. The BTB domains of RhoBTB 
allow the formation of homodimers and of 
heterodimers with other proteins of the RhoBTB 
family (Berthold et al., 2008). 
The C-terminus is a region conserved in all members 
of the RhoBTB subfamily. It predictably folds as 4 
consecutive alpha-helices and one beta-strand and 
may constitute a RING finger domain (Manjarrez et 
al., 2014). Many RING finger domains function as 
ubiquitin ligases. RhoBTB2 does not bear a CAAX 
motif that is typical for classical Rho GTPases and 
serves for localization of the protein to membranes. 
Expression 
RHOBTB2 is weakly expressed, with relatively 
higher levels in neural and cardiac tissues. It is also 
expressed in fetal tissues (Ramos et al., 2002; 
Nagase et al., 1998). During mouse embryogenesis 
high and specific expression has been observed in 
the central and peripheral nervous system and 
comparatively weaker in the gut, but the mRNA 
becomes undetectable at embryonic day 18.5 (St-
Pierre et al., 2004). One study has addressed the 
expression of RHOBTB2 during mammogenesis in 
the mouse and found that transcripts are expressed at 
low but constant levels. Attempts to study the spatial 
pattern of expression in the mammary gland using in 
situ hybridization were inconclusive because of 
undetectable mRNA levels (St-Pierre et al., 2004). 
RhoBTB2 levels increase upon initiation of prophase 
and decrease at telophase. RhoBTB2 levels also 
increase during drug-induced apoptosis. Both effects 
depend on the E2F1 transcription factor (Freeman et 
al., 2007). 
RHOBTB2 is a TP53 candidate target gene 
(Garritano et al., 2013). 
Expression of RHOBTB2 has been found decreased 
in breast, lung, bladder and stomach cancers and in 
osteosarcomas (Hamaguchi et al., 2002; Knowles et 
al., 2005; Cho et al., 2008; Shi et al., 2008; Dong et 
al., 2012; Han et al., 2013; Jin et al., 2013) as well as 
in cell lines derived from breast, lung and bladder 
tumors and head and neck squamous cell carcinomas 
(Hamaguchi et al., 2002; Knowles et al., 2005; 
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McKinnon et al., 2008) Loss of RHOBTB2 
expression has been found to correlate with promoter 
methylation in breast and bladder cancers (Shi et al., 
2008; Mehri Hajikhan et al., 2012; Han et al., 2013). 
Localisation 
The localisation of the endogenous RhoBTB2 
protein has not been investigated extensively. In 
cells ectopically expressing RhoBTB2 the protein 
tends to form aggregates in the cytoplasm 
(Aspenström et al., 2004 ; Berthold et al., 2008). 
When expressed at moderate levels it displays a 
vesicular pattern, frequently in the proximity of 
microtubules (Chang et al., 2006 ; Berthold et al., 
2008). 
Function 
RHOBTB2 was initially described as a gene 
homozygously deleted in breast cancer samples and 
was proposed as a candidate tumor supressor gene 
(Hamaguchi et al., 2002). The mechanisms by which 
RhoBTB2 exerts this and other roles remain 
speculative. When expressed in cancer cell lines, 
RhoBTB2 inhibits proliferation, induces apoptosis 
and inhibits cell migration and invasion (Mao et al., 
2011; Jin et al., 2013). 
Following functions have been proposed for 
RhoBTB2: 
1. RhoBTB2 as adaptor of cullin3-dependent 
ubiquitin ligases. The first BTB domain binds to the 
N-terminal region of Cullin 3, but not other cullins. 
RhoBTB2 is itself a substrate for the Cullin 3-based 
ubiquitin ligase complex (Wilkins et al., 2004). 
RhoBTB proteins appear to exist in an inactive state 
through an intramolecular interaction of the BTB 
domain region with the GTPase domain (Berthold et 
al., 2008). This model has been refined recently to 
show that the HSP90AA1 (Hsp90) chaperone 
machinery unlocks RhoBTB, enabling GTP binding 
and interaction with Cullin 3 and the COPS8 (COP9) 
signalosome. COP9 deneddylates Cullin 3 and 
stabilises the complex (Manjarrez et al. 2014). 
RhoBTB2, like RhoBTB1 and RhoBTB3, interacts 
with LLRC41 (leucine rich repeat containing 41, 
MUF1). MUF1 is a nuclear protein and carries a BC-
box that functions as a linker in multicomponent 
Cullin 5-dependent ubiquitin ligase complexes 
(Schenková et al., 2012). MUF1 may be a substrate 
for RhoBTB-Cullin 3 ubiquitin ligase complexes. 
The function of MUF1 is unknown, but it is 
suspected to be involved in the DNA damage 
response. 
2. RhoBTB2, cell growth and apoptosis. 
Overexpression of RhoBTB2 in the breast cancer 
cell line T-47D (a cell line that lacks RHOBTB2 
transcripts) effectively suppressed cell growth in 
vitro (Hamaguchi et al., 2002). Overexpression of 
RhoBTB2 in osteosarcoma cells significantly 
arrested cells at G1 and resulted in apoptosis (Jin et 
al., 2013). In the thyroid carcinoma cell line SW579 
treatment with recombinant RhoBTB2 for 24 hours 
inhibited proliferation and provoked an increase of 
the apoptotic ratio through the mitochondrial 
apoptotic signalling pathway (Wang et al., 2015), but 
it's not clear how the exogenously added protein 
exerts those actions. 
It was shown that overexpression of RhoBTB2 leads 
to a short-term increase in cell cycle progression and 
proliferation, but long-term expression has a 
negative effect on proliferation (Freeman et al., 
2007). The growth arrest effect has been explained 
by the downregulation of CCND1 (cyclin D1). 
Cyclin D1 is upstream of cyclin E, and the 
overexpression of any of both prevented the growth 
arrest effect of RhoBTB2 (Yoshihara et al., 2007). 
The effect on cyclin D1 is probably post-
transcriptional, but only partially dependent on 
proteasomal degradation (Collado et al., 2007). 
RHOBTB2 has been identified as a target of the 
E2F1 transcription factor. RhoBTB2 levels also 
increase during drug-induced apoptosis in an E2F1-
dependent manner, and the downregulation of 
RHOBTB2 delays the onset of apoptosis (Freeman 
et al., 2007). 
3. RhoBTB2 and chemokine expression. 
Downregulation of RhoBTB2 by RNA interference 
in primary lung epithelial cells causes a decrease in 
CXCL14 mRNA expression. The same effect was 
observed in keratinocytes and is apparently 
independent of Cullin 3-mediated protein 
degradation (McKinnon et al., 2008). 
4. RhoBTB2 and vesicle transport. Knockdown of 
endogenous RhoBTB2 hindered the ER to Golgi 
apparatus transport of a VSVG-GFP reporter and 
resulted in the altered distribution of the fusion 
protein. Ectopic RhoBTB2 distributes in a vesicular 
pattern occasionally adjacent to microtubules and an 
intact microtubule network seems to be required for 
the mobility of RhoBTB2 (Chang el al., 2006). 
5. RhoBTB2 and the actin filament system. 
RhoBTB2 displays only a moderate influence on the 
morphology and actin organisation of porcine aortic 
endothelial cells upon ectopic expression. It does not 
interact with the GTPase-binding domain of WASP, 
PAK1 or RTKN (Rhotekin), which are well-known 
effectors of many typical Rho GTPases (Aspenström 
et al., 2004). 
Homology 
There are three RhoBTB proteins in vertebrates: 
RhoBTB1, RhoBTB2 and RhoBTB3 (Figure 2). 
RhoBTB2 is very similar to RhoBTB1, while 
RhoBTB3 displays very low similarity to these.  
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Orthologues have been found in amoebae and in 
insects but they are absent in plants and fungi. 
Mutations 
Following table compiles mutations identified in 
RHOBTB2. Polymorphisms that could result in 
functional alterations are also included (marked with 
*). All mutations found in tumors are somatic. For 
mutations found in cell lines it has not been 
determined whether they are somatic or germinal. 
Implicated in 
Breast cancer 
RHOBTB2 was found homozygously deleted in 
3.5% of 200 breast tumors. A mutation analysis 
revealed two somatic missense mutations (E5 G>A 
D299N and E9 C>A P647T) and one missense 
mutation (E5 A>C D368A). In the same study 
expression of RHOBTB2 appeared extinguished in 
about 42% of 19 breast cancer cell lines (Hamaguchi 
et al., 2002).  
A more extensive mutation analysis of 100 sporadic 
breast cancers revealed some polymorphisms as well 
as two somatic mutations in the promoter (-238G>A, 
-121C>T) and 5'UTR (+48G>A) of RHOBTB2. The 
analysis of 17 CC: TXT: familial breast tumours ID: 
10062> negative for  
BRCA1/BRCA2mutations failed to reveal 
additional mutations in the coding region of 
RHOBTB2 (Ohadi et al., 2007).  
No mutations were found in the promoter or exon 7 
in 32 breast cancers of a Han Chinese population. 
This study revealed an intronic polymorphism 
common in this population; the variant IVS7 + 53C 
>G correlated with HER2 and p53 expression but not 
with age, tumor stage or estrogen or progesterone 
receptor expression (Fu et al., 2014. 
Using semi-quantitative PCR RHOBTB2 mRNA 
was found absent (56% of 87 breast tumors vs. 9% 
of normal tissue) or significantly reduced. 
RHOBTB2 Promoter methylation was detected in 
over 33% of a large collection of breast tumor 
samples and was rare in normal tissue. Loss of 
RHOBTB2 expression correlated with promoter 
methylation.  
Moreover, RHOBTB2 promoter methylation 
associated with more advance tumor stages, p53 
mutation and HER2-positive status (Han et al., 
2013).  
A similar correlation between promoter methylation 
and RHOBTB2 downregulation has been reported in 
a sample of 50 paired breast cancer and normal 
tissues. In this study promoter methylation was 
found more frequently associated to progesterone 
receptor negative tumors (Tang et al., 2014).  
 
Localisation of mutations found in the coding region of RHOBTB2 in tumors and cancer cell lines. Note that most missense 
mutations affect the first BTB domain of the protein and reside in exon 5. 
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Significantly more frequent promoter methylation 
was also found in a collection of 50 breast tumor 
(34%) and blood samples (46%) compared to normal 
samples (20% or less) in another study (Mehri 
Hjikhan et al., 2012).  
A frequent pattern of loss of RHOBTB2, CDH1 and 
TP53 together with gain of COX2 and MYC was 
found in a single cell in situ hybridization analysis of 
13 samples simultaneously carrying ductal 
carcinoma in situ (DCIS) and invasive ductal 
carcinoma (IDC) of the breast. DCIS is the precursor 
lesion for invasive breast cancer. The study aimed at 
understanding the dynamics of genomic alterations 
in the progression from DCIS to IDC and included 
several oncogenes and tumor suppressor genes 
(Heselmayer-Haddad et al., 2012). 
Oncogenesis 
RHOBTB2 was proposed as a candidate tumor 
suppressor gene based on the fact that its re-
expression in T-47D (a breast cancer cell line that 
lacks RHOBTB2 transcripts) caused growth 
inhibition, whereas expression of the mutant D299N 
did not have the same effect. Neither the D299N nor 
a D368A mutant found in some tumors presented 
abolished binding to Cullin 3 (Hamaguchi et al., 
2002). Overexpression of RhoBTB2 in T-47D 
inhibits cell proliferation and colony formation while 
promoting apoptosis, but was found not to influence 
the invasion and migration ability of the cells in a 
Transwell system (Mao et al., 2011).  
The mutations found in the promoter and 5'UTR of 
RHOBTB2 in some breast tumors might affect 
regulation of gene expression (Ohadi et al., 2007). 
Lack of RHOBTB2 expression in T-47D is 
apparently due to RHOBTB2 promoter methylation 
(Han et al., 2013). Methylation of RHOBTB2 and 
other genes in peripheral blood is a potential 
epigenetic marker for predicting the risk of breast 
cancer development (Khakpour et al., 2015).  
Ectopic expression of RHOBTB2 in two human 
metastatic breast cancer cell lines, MDA-MB-231 
and MDA-MB-435, inhibits cell migration and 
invasiveness through a mechanism that involves 
upregulation of the metastasis suppressor BRMS1 
and decreased phosphorylation of EZR (ezrin) and 
Akt2 (Ling et al., 2010). Ezrin is a cytoskeleton and 
signaling molecule that regulates cell adhesion, 
migration and invasion. Akt2 is a kinase involved in 
invasiveness of breast cancer cells and is able to 
phosphorylate ezrin (Freeman and Cress 2010) 
Lung cancer 
Note 
A mutation analysis revealed a missense mutation 
(E5 T>G Y284D) in a lung tumour cell line. In the 
same study expression of RHOBTB2 appeared 
extinguished in about 50% of 14 lung cancer cell  
 
lines (Hamaguchi et al., 2002).  
In an immunohistochemistry study of 172 tissue 
samples from different subtypes of lung 
adenocarcinomas frequent (70% of tumors) 
downregulation of RHOBTB2 was found that 
correlated with the degree of invasiveness (Dong et 
al, 2012). 
Oncogenesis 
The Y284D mutant protein presents abolished 
binding to Cullin 3 and has consequently a longer 
half-life than the wild type protein.  
The mutation resides in the dimerisation interface of 
the first BTB domain and could prevent proper 
folding (Wilkins et al., 2004). 
Gastric cancer 
Note 
In a study on primary gastric cancers loss of 
heterozygosity was found in 29% of 95 tumors. 
Sequence analysis identified several polymorphisms 
and one missense somatic mutation (E5 C>T 
R275W) of unknown effect (Cho et al., 2008). 
Bladder cancer 
Note 
A loss of heterozygosity (LOH) and mutation 
analysis on 54 tumour samples and 32 cell lines of 
bladder cancer revealed LOH in the target region in 
42% of informative tumours and 38% of cell lines. 
Sequence analysis revealed numerous 
polymorphisms and one missense somatic mutation 
(E5 G>C E349D) of unknown effect.  
One polymorphism (E7 G>A G561S) may have 
some functional effect.  
In addition, expression of RHOBTB2 was found 
reduced by 2 to 20-fold in 9 of 12 cell lines with 
predicted LOH in the region of interest (Knowles et 
al. 2005). 
Significantly higher RHOBTB2 promoter 
methylation correlated with decreased expression 
compared to normal tissue was reported in a study of 
75 bladder cancer samples (Shi et al., 2008). 
Head and neck squamous cell 
carcinoma 
Note 
Expression of RHOBTB2 was found reduced in four 
clonal keratinocyte cell lines derived from patients 
with HNSCC.  
This was accompanied by reduced expression of the 
chemokine CXCL14 (McKinnon et al., 2008). 
Oncogenesis 
RhoBTB2 seems to be required for expression of the 
chemokine CXCL14 (McKinnon et al., 2008). 
CXCL14 controls leukocyte migration and 
angiogenesis and its expression is frequently lost in 
diverse epithelial tumours, including most HNSCCs. 
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Osteosarcoma 
Note 
Expression of RhoBTB2 was analysed in 121 
osteosarcoma specimens and was found decreased 
compared to normal regions of the specimens. 
Expression correlated with the primary location and 
local recurrence of the tumor (Jin et al., 2013). 
Oncogenesis 
RhoBTB2 may affect the cell cycle. Overexpression 
of RhoBTB2 in osteosarcoma cells significantly 
arrested cells at G1 and resulted in apoptosis (Jin et 
al., 2013). 
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